Kyverna Therapeutics Shares Drop Amid Analyst Target Cuts
Shares of Kyverna Therapeutics (NASDAQ:KYTX) fell nearly 13% following a price target reduction by JPMorgan and sell calls from other analysts, despite the company reporting better-than-expected Q1 results. The stock had been on an upward trend but is now facing downward pressure due to revised expectations.
Topics: clinical-stage biotech JPMorgan Kyverna Therapeutics price target cut